Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderate to Severe Psoriasis
Conditions
Interventions
VTX958 Dose A
VTX958 Dose B
+3 more
Locations
63
United States
Local Site # 840012
Birmingham, Alabama, United States
Local Site # 840006
Birmingham, Alabama, United States
Local Site # 840028
Phoenix, Arizona, United States
Local Site # 840032
Bryant, Arkansas, United States
Local Site # 840041
North Little Rock, Arkansas, United States
Local Site # 840031
Fountain Valley, California, United States
Start Date
November 17, 2022
Primary Completion Date
September 25, 2023
Completion Date
December 20, 2023
Last Updated
September 19, 2024
NCT06857942
NCT06979453
NCT07449234
NCT07116967
NCT07250802
NCT07449702
Lead Sponsor
Ventyx Biosciences, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions